Allergy
Conditions
Brief summary
This study is designed to assess bioequivalence between two products used for treatment of allergy.
Detailed description
This study is designed to evaluate if a test formulation of cetirizine 10 mg orodispersible tablet (ODT) taken with and without water is bioequivalent to a marketed reference formulation of cetirizine 10 mg tablet (Benadryl One A Day, McNeil Products Ltd, UK) taken with water. This study will also evaluate the tolerability of test and reference formulations.
Interventions
DRUGCetirizine
A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
Sponsors
McNeil AB
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female subjects * Volunteers aged of at least 18 years but not older than 55 years * Subjects will have a Body Mass Index (BMI) greater than or equal to 18.50 and below 30.00 kg/m2 * Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study * Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance * Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis) * Has signed and dated the informed consent document, indicating that the subject has been informed of all pertinent aspects of the study * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion criteria
* Seated pulse rate below 45 bpm or higher than 90 bpm at screening * Seated blood pressure below 90/60 mmHg or higher than 140/90 mmHg at screening * Relationship to persons involved directly with the conduct of the study (i.e., principal investigator; sub-investigators; study coordinators; other study personnel; employees or contractors of the sponsor or Johnson & Johnson subsidiaries; and the families of each) * Presence of any tongue piercings * Presence of braces * Females who are pregnant or are lactating * Females of childbearing potential or males with a female partner of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study * Females who are pregnant according to a positive serum pregnancy test * Any medical history or condition, or use of any drug or medication, that the investigator determines could compromise subject safety or the evaluation of results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Plasma Concentration | During 32 hours post-dose | Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered, measured in nanograms/milliliter (ng/mL) |
| Bioavailability [AUC(0-t)] | During 32 hours post-dose | Bioavailability \[AUC(0-t)\] is a measure of how much of the drug reaches the person's bloodstream within a given period of time for the body to use. The extent of product bioavailability is estimated by the area under the blood concentration vs time curve. The Area Under the Curve (AUC) is calculated by plotting the drug's blood levels on a graph at different times during the set period. The area under this curve reflects the amount of drug exposure in the set time period, calculated as hour \* nanograms (ng) per milliliter (mL). |
| Bioavailability Extrapolated to Infinity [AUC (0-∞)] | 32 hours post-dose | Bioavailability Extrapolated to Infinity \[AUC (0-∞)\] is a calculated measure of how much of the drug will ever reach the person's bloodstream for the body to use. AUC (0-∞) stands for the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (forever). It is obtained from calculating AUC (0-t) plus AUC (t-∞). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the Curve to the Tmax of the Reference Products | During 32 hours post-dose | Area under the plasma concentration versus time curve to the time of the maximum concentration of the reference products (AUCReftmax) |
| Time of Maximum Concentration | During 32 hours post-dose | The time at which maximum concentration is reached (Tmax) |
| Mean Residence Time | During 32 hours post-dose | The average amount of time a particle (e.g., a drug substance molecule) remains in a compartment or system. |
| Relative percentage of AUCT with respect to AUC∞ (AUCT/∞) | During 32 hours post-dose | AUCT is the area under the plasma concentration verses time curve from start of drug administration until the time of the last measurable plasma concentration. AUC∞ is the area under the plasma concentration versus time curve from start of drug administration until extrapolated infinite time. AUCT/ AUC∞ is an inversed measure of how large the extrapolated area under the curve is. |
| Terminal Elimination Rate Constant | During 32 hours post-dose | The Terminal Elimination Rate Constant (Lamda z) is the time required to eliminate half the administered dose |
| Terminal Phase Plasma Half-Life | During 32 hours post-dose | Terminal phase plasma half-life (t ½) is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, rather than the time required to eliminate half the administered dose. |
Countries
Canada
Outcome results
None listed